$SGEN
AI AnalysisGenerated on May 11, 2026
AI Score
Strong Sell$SGEN
Seagen Inc.
$SGENNASDAQHealthcareLarge-Cap
Seagen was acquired by Pfizer in 2023 for its antibody-drug conjugate cancer treatments.
Market Cap
$0.0B
Revenue (TTM)
$0.0B
N/A
Net Income (TTM)
$0.0B
N/A
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$0-$0
Beta
0.80
Dimension Scores
Fundamental
5Technical
5Sentiment
5Risk / Reward
5Momentum
5Financial Health
Profitability
10weak
Growth
8weak
Liquidity
13strong
Solvency
7moderate
Efficiency
3moderate
Valuation, technical analysis, investment thesis, risk assessment and more for $SGEN
Free · No credit card required
Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.